Telescope receives SDL purchase order from KPBMA

Executive Summary

• Telescope Innovations Corp. has secured a purchase order from the Korean Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA) for one of its self-driving lab (SDL) platforms.
• The SDL will be installed at a new R&D facility in Seoul within weeks, serving as the core component of Korea's first AI-driven training hub for drug discovery.
• This transaction marks Telescope's entry into the South Korean market and establishes a strategic partnership with KPBMA to promote the adoption of autonomous laboratory technologies in Asia.

Key Details

• Transaction: Purchase of one self-driving lab (SDL) platform by KPBMA.
• Implementation Timeline: Installation scheduled to occur within a few weeks of the announcement.
• Location: New R&D facility in Seoul, South Korea.
• Strategic Context: The SDL will serve as the foundation for the Convergence AI Institute for Drug Discovery (CAIID), KPBMA's initiative to promote automation and AI-driven experimentation.
• Partnership Scope: Telescope and KPBMA are building a strategic partnership focused on SDL deployment and adoption across Korea's pharmaceutical sector.
• Market Significance: This represents Telescope's first self-driving lab deployment in South Korea, positioning the company at the center of the growing Asian market for lab automation and digital R&D transformation.
• Technology Description: The SDL utilizes robotics, inline analytics, and AI/machine learning to run continuous closed-loop workflows, capable of completing hundreds of experimental cycles faster and with greater consistency than manual work.

Notable Quotes

• Junhee Pyo, CAIID Vice-Chief: "We anticipate that this self-driving lab will bring significant innovation to new drug development processes in Korea... We also look forward to active global collaboration to facilitate technological exchange in this rapidly advancing field."
• Jason Hein, Telescope Chief Technology Officer: "Delivering our first self-driving lab in South Korea will mark a major milestone for Telescope's intelligent automation technology and for globally shifting the way pharmaceutical R&D is done... we look forward to leading the deployment and adoption of SDLs in Asia."
• Henry Dubina, Telescope Chief Executive Officer: "Asia represents one of the fastest-growing markets for lab automation and the digital R&D transformation... We see this as the foundation for broader regional adoption of SDLs across research institutes and biopharma companies seeking faster, data-driven development."